Investors Hub
Welcome to Orchid Pharma Investor Center
Welcome to Orchid Pharma's investor center. Everything our investor ask for financial results, the latest annual report, governance policies and statutory disclosures lives here, organised the way regulators expect and humans can navigate.
Explore more
.webp)
.webp)
Overview
Financial Information
Reports
Governance
Disclosure & Filings
Investors Information
Investors Facilitation
Strategic Alerts
Dividend
Disclosure as per Regulation 46
Archive
Compliance Officer
Overview
Revenue from Ops
152₹ CR
FY 2026 YoY Change
EBITDA Margin
58%
FY 2026 YoY Change
Profit After Tax
68₹ CR
FY 2026 YoY Change
EPS
6.03₹
Diluted · FY 2026
All filings on this page are also available on the websites of BSE Limited and the National Stock Exchange of India. For grievances, please write to the Compliance Officer or escalate via SEBI SCORES under the Strategic Alerts tab.
Read FAQs
About the company
From molecule to medicine, through vertical integration and responsible stewardship.
Established in 1992 and now part of the Dhanuka Group, Orchid Pharma is an integrated pharmaceutical company addressing complex healthcare challenges from API manufacturing and finished formulations to NCE discovery across regulated and emerging markets.
We operate the world's largest cephalosporin API portfolio, with USFDA-approved sterile manufacturing and full backward integration from intermediates to API. Our facilities are accredited by US FDA, UK MHRA, EU GMP, PMDA Japan and TGA Australia.
Orchid Pharma Limited is publicly listed (NSE: ORCHPHARMA | BSE: 524372) and part of the Dhanuka Group.
At a glance
Operating footprint
A snapshot of where Orchid operates and the scale of its commercial reach. Numbers will be filled in from the latest investor pack.
Manufacturing facilities
USFDA-approved sterile and oral-dosage units, with dedicated cephalosporin API and intermediates capacity.
Research & Development
Non-infringing route R&D, green chemistry, peptide engineering and regulatory dossier filings.
Global accreditations
US FDA · UK MHRA · EU GMP · PMDA Japan · TGA Australia · WHO-GMP.
Therapeutic focus
Anti-infectives at the core; NCE pipeline including India’s first invented globally-approved antibiotic (EXBLIFEP®).
Workforce
Employees across manufacturing, R&D, quality and corporate functions.
Listings
NSE: ORCHPHARMA | BSE: 524372
Learn more
Stock information
Real-time stock value
The price chart, intraday data and shareholder distribution will plug in here. Below is the structural placeholder so layout, copy and access points are reviewable now.
Latest updates
What's new from Orchid
A chronological feed of intimations, press releases and market disclosures filed with the exchanges.
Document
Date
Format
Investor contacts
Reach the people who can help
For securities matters, queries and grievances. We aim to respond within working days.
Authorised Person to determine materiality of information
Nodal officer for IEPF related matters
Investor Grievance Desk
investorrelations@orchidpharma.com
For queries, complaints and SCORES escalations
Corporate Information.
Orchid Pharma Limited
Corporate Identification Number - L24222TN1992PLC022994
Registered Office:
Financial results
Quarterly & Annual results
Audited / unaudited standalone and consolidated results filed with the exchanges.
FY 2026
Document
Year
Format
Financial Statements
As filed with the exchanges and the Registrar of Companies.
FY 2026
Document
Date
Format
Earnings calls
Calls, transcripts & recordings
Quarterly investor & analyst calls, with audio recordings and transcripts.
FY 2026
Quarter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Subsidiaries
Subsidiary information
Disclosures pertaining to material and other subsidiaries of the company financials and
supporting documents.
Subsidiary
Financials
Material Subsidiary
Document
Date
Format
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Orchid Europe Limited
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Orchid Europe Limited
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Orchid SA Financials
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Orchid Bio-Pharma Limited
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Orchid Bio-Pharma Limited
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2024-25
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2024-25
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2024-25
Format:
PDF
Other information
Document:
Orchid Bio-Pharma Limited
Year:
F.Y. 2024-25
Format:
PDF
Other information
Subsidiary · Financials
Subsidiary financials
Audited financial statements of material subsidiaries, filed under Section 129(3) of the Companies Act, 2013.
Subsidiary
Financials
Material Subsidiary
Document
Date
Format
Subsidiary · Other
Other subsidiary disclosures
Board resolutions, name changes, capital infusions and other intimations related to subsidiaries.
Subsidiary
Financials
Material Subsidiary
Document
Date
Format
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Orchid Europe Limited
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2020-21
Format:
PDF
Other information
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Orchid Europe Limited
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2021-22
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Orchid SA Financials
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Orchid Bio-Pharma Limited
Year:
F.Y. 2022-23
Format:
PDF
Other information
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Orchid Bio-Pharma Limited
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2023-24
Format:
PDF
Other information
Document:
Orchid Pharmaceuticals INC
Year:
F.Y. 2024-25
Format:
PDF
Other information
Document:
Bexel Pharmaceuticals
Year:
F.Y. 2024-25
Format:
PDF
Other information
Document:
Diakron Pharmaceuticals
Year:
F.Y. 2024-25
Format:
PDF
Other information
Document:
Orchid Bio-Pharma Limited
Year:
F.Y. 2024-25
Format:
PDF
Other information
Annual reports
Annual results
The Annual Report combines our financial performance with disclosures on governance, sustainability and stakeholder value.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
BRSR
Business Responsibility & Sustainability Report
ESG performance, principle-wise disclosures and assurance as part of the integrated Annual Report.
FY 2026
Credit rating
Credit rating
Latest ratings on long-term and short-term facilities, with rationale documents from the agencies.
Secretarial compliance
Annual Secretarial Compliance Report
Filed under Reg. 24A of SEBI (LODR), certified by a Practicing Company Secretary.
Document
Date
Format
Other reports
Other statutory & voluntary reports
Documents and details for this section are filed periodically and will populate here.
FY 2026
Document
Date
Format
Board composition
The people steering Orchid
A balanced Board combining executive leadership, non-executive oversight and independent voices, in line with SEBI (LODR) requirements.
Mr. Ram Gopal Agarwal
Chairman, Non-Executive Director
Founder Chairman of the Dhanuka Group. Transformed a single company into a Rs 1,000+ Crore organisation rated thrice by Forbes as 'Best Under a Billion.' Former Chairman of CCFI (Crop Care Federation of India). Recipient of Lifetime Achievement Award at Agri Business Summit 2019.
Mr. Manish Dhanuka
Managing Director
B. Tech in Chemical Engineering from IIT Delhi. M.S. from University of Akron, USA. 25+ years in pharmaceutical research, manufacturing, and commercialisation. Founded Dhanuka Laboratories in 1997. Led the acquisition of Orchid Pharma in 2020.
Mr. Mridul Dhanuka
Whole-Time Director
Chemical Engineer with an MBA. Associated with Dhanuka Group since 2005. Expertise in production, supply chain, and operational efficiency. Led the expansion of manufacturing facilities including the world-class facility at Keshwana, Rajasthan.
Mr. Arjun Dhanuka
Mr. Arjun Dhanuka
Graduate of Delhi University. Over a decade of experience in pharmaceutical operations. Currently supervises operations at Synmedic Laboratories. Focuses on R&D leadership and quality-driven growth.
Ms. Tanu Singla
Independent Director
Qualified Company Secretary. LLB and Diploma in Finance Management. 10+ years as Company Secretary across Real Estate and Media industries.
Dr. Dharam Vir
Independent Director
Ph.D. in Synthetic Organic Chemistry. More than 3 decades of experience in pharmaceutical R&D and intellectual property. Former leadership at Ranbaxy (20 years) and Jubilant Generics (11 years). 100+ patents and patent applications.
CA Dr. Manoj Goyal
Independent Director
Fellow Member, ICAI. Ph.D. and LLB. 24+ years in taxation, audit, finance, and corporate law.
Ms. Shubha Singh
Independent Director
Company Secretary since 2003. CFA, MBA (International Business) from IMT Ghaziabad, LLB. 23 years in secretarial, finance, and legal functions. Winner: Best Non-Executive Director Award, MMB Iconic Women Directors of India 2023.
Board committees
Five committees, each with a specific remit
Composition, charters and meeting attendance are disclosed in the Corporate Governance Report within our Annual Report.
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Shri Manoj Kumar Goyal
Designation:
Non-Executive-Independent Director
Position:
Chairman
Name of the Member:
Ms. Tanu Singla
Designation:
Non-Executive-Independent Director
Position:
Member
Name of the Member:
Shri Mridul Dhanuka
Designation:
Whole Time Director
Position:
Member
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Dr Dharam Vir
Designation:
Non-Executive-Independent Director
Position:
Chairman
Name of the Member:
Shri Manoj Kumar Goyal
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Ms. Tanu Singla
Designation:
Non-Executive- Independent Director
Position:
Member
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Dr. Dharam Vir
Designation:
Non-Executive-Independent Director
Position:
Chairman
Name of the Member:
Shri Manoj Kumar Goyal
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Mr.Arjun Dhanuka
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Ms. Shubha Singh
Designation:
Non- Executive Independent Director
Position:
Member
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Dr. Dharam Vir
Designation:
Non-Executive-Independent Director
Position:
Chairman
Name of the Member:
Shri Manoj Kumar Goyal
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Mr.Manish Dhanuka
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Mr.Mridul Dhanuka
Designation:
Whole Time Director
Position:
Member
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Dr. Dharam Vir
Designation:
Non-Executive-Independent Director
Position:
Chairman
Name of the Member:
Mr.Manish Dhanuka
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Mr.Mridul Dhanuka
Designation:
Whole Time Director
Position:
Member
Name of the Member:
Shri. Sunil Kumar Gupta
Designation:
Chief Financial Officer
Position:
Member
Name of the Member:
Dr. A Chandrasekar
Designation:
Head-API
Position:
Member
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Mr.Manish Dhanuka
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Mr.Mridul Dhanuka
Designation:
Whole Time Director
Position:
Member
Name of the Member:
Name of the Member
Designation:
Designation
Position:
Position
Name of the Member:
Mr.Manish Dhanuka
Designation:
Non-Executive Director
Position:
Member
Name of the Member:
Mr.Mridul Dhanuka
Designation:
Whole Time Director
Position:
Member
Name of the Member:
Mr. Sunil Kumar Gupta
Designation:
Chief Financial Officer
Position:
Member
Name of the Member:
Mr.Kapil Dayya
Designation:
Company Secretary
Position:
Member
Independent Directors
The people steering Orchid
A balanced Board combining executive leadership, non-executive oversight and independent voices, in line with SEBI (LODR) requirements.
Ms. Tanu Singla
Independent Director
Qualified Company Secretary. LLB and Diploma in Finance Management. 10+ years as Company Secretary across Real Estate and Media industries.
Dr. Dharam Vir
Independent Director
Ph.D. in Synthetic Organic Chemistry. More than 3 decades of experience in pharmaceutical R&D and intellectual property. Former leadership at Ranbaxy (20 years) and Jubilant Generics (11 years). 100+ patents and patent applications.
CA Dr. Manoj Goyal
Independent Director
Fellow Member, ICAI. Ph.D. and LLB. 24+ years in taxation, audit, finance, and corporate law.
Ms. Shubha Singh
Independent Director
Company Secretary since 2003. CFA, MBA (International Business) from IMT Ghaziabad, LLB. 23 years in secretarial, finance, and legal functions. Winner: Best Non-Executive Director Award, MMB Iconic Women Directors of India 2023.
Familiarisation
Familiarisation Programmes for Independent Directors
Documents and details for this section are filed periodically and will populate here.
Document
Date
Format
Policies
Codes, charters & policies
The full library of corporate policies that govern how Orchid operates from related-party transactions to whistle-blower protections.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Format
Insider trading
Disclosures under PIT Regulations
Disclosures by promoters, designated persons and connected persons under SEBI (Prohibition of Insider Trading) Regulations.
FY 2026
Document
Date
Format
Stock Exchange and Filings
FY 2026
Quarter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
FY 2026
Quarter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
FY 2026
Quarter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Integrated Filings
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
General Updates
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
General meetings
AGMs, EGMs & Postal Ballots
Notices, proceedings, scrutiniser reports and voting results from the company's general meetings.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Analyst meets
Analyst Meets
Notice of meetings with institutional investors / analysts under Reg. 30 of LODR.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Investor presentations
Latest decks
Quarterly performance updates and one-pagers shared with investors and analysts.
Newspapers
Newspaper advertisements
Statutory notices and financial result publications in business newspapers.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format
Notifications
Notifications & Circulars
Documents and details for this section are filed periodically and will populate here.
Document
Format
Annual returns
Annual Returns (MGT-7)
Filed under Sec. 92 of the Companies Act, 2013.
Investor downloads
Investor download centre
Documents and details for this section are filed periodically and will populate here.
Access Investor Grievance & Resolution Portal
Investor Login
SCORES
SEBI SCORES Investor escalation portal
Documents and details for this section are filed periodically and will populate here.
IEPF
Investor Education & Protection Fund
Documents and details for this section are filed periodically and will populate here.
Re-lodgement
Special Window for re-lodgement of Transfer of Physical Shares
Documents and details for this section are filed periodically and will populate here.
FAQs
Frequently asked, plainly answered
If your question isn't here, write to the investor team we'll respond within working days.
How can I update my address / bank mandate?
Holders in dematerialised form should approach their Depository Participant (DP). Holders in physical form may write to the RTA details on this page.
Merger & Amalgamation
Scheme documents & updates
Documents and details for this section are filed periodically and will populate here.
Merger and Amalgamamatioin
QIP
Document
Format
Regulation 46
Disclosure as per Regulation 46
Documents and details for this section are filed periodically and will populate here.
Sl. No.
Particulars
Weblink
14
Details of agreements entered into with the media companies*
Not Applicable
16
New name and old name of the listed entity*
Not Applicable
27
Employee Benefit Scheme
Not Applicable
Archive
Archive of older disclosures
Documents and details for this section are filed periodically and will populate here.
FY 2026
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Document
Date
Format